Skip to Main Content

Paper Details

Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Cancer Cell
117
2019
ABL1, ABL1T315I, ABL1T315I-, ATP, Asciminib, BCR, Ph+ clinical isolates, Philadelphia chromosome, Philadelphia chromosome-positive (Ph+) leukemia, Ponatinib, asciminib, cell lines, leukemic, leukemic clones, myristoyl, patients, ponatinib, tyrosine, tyrosine kinase
Author NameAffiliation
Christopher A EideOHSU Knight Cancer Institute, Oregon Health & Science University, USA Howard Hughes Medical Institute
Matthew S ZabriskieHuntsman Cancer Institute, University of Utah
Hein ThanHuntsman Cancer Institute, University of Utah
Anna Reister SchultzOHSU Knight Cancer Institute, Oregon Health & Science University
Phillip M ClairHuntsman Cancer Institute, University of Utah
Amber D BowlerHuntsman Cancer Institute, University of Utah
Anthony D PomicterHuntsman Cancer Institute, University of Utah
Dongqing YanHuntsman Cancer Institute, University of Utah
Anna SeninaHuntsman Cancer Institute, University of Utah
Jeffrey W TynerOHSU Knight Cancer Institute, Oregon Health & Science University
Dong Wook KimLeukemia Research Institute, The Catholic University of Korea, Seoul St Mary's Hospital
Dong Wook KimLeukemia Research Institute, The Catholic University of Korea, Seoul St Mary's Hospital
Cristina E TognonOHSU Knight Cancer Institute, Oregon Health & Science University, USA Howard Hughes Medical Institute
Thomas O'HareHuntsman Cancer Institute, University of Utah
Brian J DrukerOHSU Knight Cancer Institute, Oregon Health & Science University, USA Howard Hughes Medical Institute
Michael W DeiningerHuntsman Cancer Institute, University of Utah
  • 1 - 16

Datasets